Preliminary Report

Intralesional Tetracycline Injection, Pinch Technique, and Canthopexy for the Treatment of Severe Festoons: Preliminary Results

Sergio Lessa, MD, PhD; João Pontello, MD, PhD; Deilton Duarte, MD; and Diogo Lobão, MD

Abstract

Background: Many techniques have been presented for the treatment of lower eyelid festoons, but no singular technique has become dominant.

Objectives: The authors describe the safety and efficacy of intralesional tetracycline injection, the pinch technique, and canthopexy for the treatment of severe festoons.

Methods: Institutional board review approval was obtained, and a retrospective chart review was performed on 15 consecutive patients who had received 2% tetracycline injections to treat lower eyelid large festoons between February 2017 and February 2020. Three months after the last injection, a series of patients underwent the surgical procedure: pinch technique and canthopexy bilaterally.

Results: Clinical and photographic records were reviewed, and 12 patients were included in the analysis. Three patients did not return for follow-up after the injection series. Of the 12 patients, there were 3 male patients and 9 female patients, with an average age of 66.6 years. The mean volume injected in each festoon was 0.43 mL, and the mean follow-up was 313 days. A series of injections with a 3-month time interval were performed for patients with a partial response to the initial injection. There was no evidence of complications at the site of the injection. Three months after the last injection, these 12 patients underwent complementary surgical treatment, which included pinch resection and canthopexy.

Conclusions: These preliminary results suggest that intralesional injections of tetracycline 2% may offer a safe option to treat lower eyelid festoons. This noninvasive procedure represents adjunct benefits to complementary surgical therapy.

Level of Evidence: 4

Eyelids and periorbital changes are the first detectable signs of aging. Among the many changes that occur, festoons and malar bags present a challenge to the treating physician. Furnas was the first to describe the anatomic changes of festoons as well as an approach to treating these conditions. Festoons are caused by laxity and degeneration of the skin and orbicularis muscle. Kpodzo et al described festoons as “cascading hammocks of lax skin and orbicularis muscle that hang between the medial and lateral canthi and may or may not contain herniated fat.”

Festoons are normally located within the prezygomatic region from the Division of Plastic Surgery, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

Corresponding Author:
Dr Sergio Lessa, Av. Ataulfo de Paiva, Leblon, Rio de Janeiro, RJ, Brazil 135/716, 22440-901.
E-mail: sergiolessa.md@gmail.com
space, which is bound by the orbitomalar ligament superiorly and the zygomaticocutaneous ligament inferiorly. Muzaffar et al cited the elongation of the orbitomalar ligament as a key to aging changes of the lower eyelid and the appearance of malar mounds. Anatomic researchers Pessa and Garza proposed that festoons result from malar edema progression, causing malar mounds and eventually resulting in festoons. The etiology of festoons is thus multifactorial.

Many different surgical approaches have been attempted with variable success rates. The invasive treatment of malar and festoon bags depends on the diagnosis, the patient’s age, and the severity of the lesions. The treatment options include microsuction, myocutaneous flap, orbicularis muscle resection, midface lifts and direct excision of the festoon. Nonsurgical treatment options consist of interventions with variable results and may represent adjunct benefits to surgical therapies. Some of these options include Kinesio tape to minimize festoons, the use of radiofrequency microneedling, laser management of festoons, hyaluronidase injection, tetracycline-doxycycline injections. Two studies focused on the use of these antimicrobials in the periorbital treatment of festoons and provided new insight into the field. However, the applications of these drugs provide only initial results, thus requiring more detailed studies to determine the safety and efficiency of this treatment.

In 2020, Chon et al evaluated the long-term patient experience with tetracycline injections for treatment of festoons, a retrospective review of 102 patients. In this review, intralesional tetracycline injections appear to improve festoons in the majority of patients with very few side effects. The purpose of this report is to review the authors’ preliminary experience injecting tetracycline 2% and the associated surgical procedure for the treatment of aesthetically undesirable lower eyelid festoons.

**METHODS**

The study was approved by the ethics and research committee (Plataforma Brasil System, approved under number: 3.081.115) and conducted according to ethical standards of the Helsinki Declaration 1964 and its subsequent amendments. A retrospective chart review was performed on 15 consecutive patients who had received 2% tetracycline injections to treat lower eyelid large festoons at the Department of Plastic Surgery of State University of Rio de Janeiro between February 2017 and February 2020. All patients with acquired festoons gave a history of puffiness and bags between the lower eyelids and midface. The deformities began with aging and were not present in youth. Data collection included the following: age, sex, date and volume of injection, number of injections, and subjective complaints. Statistical analysis was performed with the aid of SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Machintosh, Version 21.0. Armonk, NY). Continuous variables are described as the mean, standard deviation (SD), and minimum and maximum values. Analytical statistics were performed using the Wilcoxon signed-rank test with a significance level when \( P \) was less than 0.05.

We used the same method as Perry et al to obtain a reconstituted tetracycline 2% solution from 02 g tetracycline HCl USP powder (Fagron, St. Paul, MN), adding sterile water, and filtering to rebuild tetracycline 2% solution. The solution was injected into the cavity of the festoon in several planes between the orbicularis and deep fascia using a 1-mL syringe attached to a 30-gauge needle (Video). All the procedures were performed at the outpatient clinic without sedation.

The volume of injection was guided by the volume of the festoon. Repeat injections were performed in patients as needed for residual volume following an observation period of 3 months. Three months after the last injection, a series of patients underwent the surgical procedure, which included “pinch resection” and muscle suspension canthopexy bilaterally. The pinch technique can be performed under local anesthesia. Using a 7- to 8-mm skin pinch technique with the patient in an upward gaze, the greatest amount of skin is drawn upward for excision to avoid traction on the lower lid margin.

In all cases, the orbicularis is suspended by a single suture anchoring the lateral portion of the pretarsal orbicularis muscle to the lateral orbital periosteum. When the suture is tied, it pulls the muscle upward and laterally, creating a tight sling under the lower eyelid. Additional elevation is done through another canthopexy, affixing the dermis of the lower eyelid wound to the periosteum, above the lateral angle. A running suture is used for the final closure (Video). All pretreatment and posttreatment photographs were taken in a standardized position and were reviewed by 2 independent physicians.
RESULTS

A total of 15 patients underwent tetracycline 2% injection for the treatment of large bilateral lower eyelid festoons. Clinical and photographic records were reviewed, and 12 patients were included in the analysis. Three patients were excluded because they had not returned for follow-up after a series of injections were completed. During our phone contacts, these patients expressed satisfaction with the injection results and were not ready to return for further treatment. It is important to mention that patients who are attended in our service arrive by way of a central referral system of the Public Health Service of the State of Rio de Janeiro. Often, they live extremely far making travel, especially in pandemic times, more challenging. Of the 12 included patients, 24 treatment sides were analyzed. After tetracycline 2% injections, there were 3 male patients and 9 female patients with an average age of 66.67 years (range, 64-70 years with a SD of 2.16 years). All patients received bilateral injections at the outpatient clinic without sedation. The mean injected volume of tetracycline in each festoon was 0.43 mL (range, 0.35-0.60 mL and SD 0.91 mL). Patients returned for follow-up 1 week after each injection at 3-month intervals. At each return visit, the reduction of volume and the degree of aesthetic improvement determined subsequent injections. In our cases of very severe festoons, patients underwent a series of either 3 or 4 injections. The mean number of injections performed per site was 3.16 (range, 3-4). The mean follow-up was 313 days. Patients returned for follow-up 1 week after each injection at 3-month intervals. At each return visit, the reduction of volume and the degree of aesthetic improvement determined subsequent injections. In our cases of very severe festoons, patients underwent a series of either 3 or 4 injections. The mean number of injections performed per site was 3.16 (range, 3-4). The mean follow-up was 313 days.

The tetracycline family consists of compounds with antimicrobial actions. They also exhibit numerous nonantimicrobial properties. For example, they produce growth factor-like activity that stimulates fibroblast proliferation and have also demonstrated the ability to inhibit matrix metalloproteinases from numerous cellular tissues to promote collagen and fibrin deposition. Tetracycline compounds have been used to successfully achieve chemical pleurodesis and to treat a variety of ophthalmic conditions, such as chronic bulbar chemo.

Three recent studies focused on the use of antimicrobials in the treatment of malar mounds and festoons. In 2 of them, the intralesional injection of tetracycline 2% showed improvement in the contour to correct the festoons. Another antibiotic in the tetracycline family, doxycycline, was used at a concentration of 10 mg/mL to correct festoons and malar edema. Clinically, tetracycline seems to improve festoons within 3 months. Three months after the last injection, 12 patients underwent bilateral muscle suspension canthopexy (Table 1).

The volume differences between the first injection and the second and third injections were analyzed using the Wilcoxon signed-rank test, with a P-value lower than 0.05 indicating significance. The differences observed between the first and second injections on the right side resulted in a P-value of 0.46 and the first compared with the third had a P-value of 0.26. In the left side analysis, a P-value of 0.46 was obtained for the comparison between the first and the second sides, and a P-value of 0.24 was obtained for the comparison with the third side. These results show that the differences in volume are statistically significant. The final results of the association of the procedures showed a significant cosmetic improvement, although in 2 patients, very discreet unilateral festoon residue remained even after surgery. Both these patients were nonetheless satisfied with the results and did not wish to undergo further surgical correction as was offered to them. Treatments and posttreatment photographs are shown in Figures 1-4.
Figure 1. A 68-year-old male with cascading festoons (A) before treatment; (B) showing a decrease in festoon volume after 3 bilateral injections of tetracycline at 9 months; and (C) postsurgery, month 10 of treatment, showing improvement with some residual festoon presence on the left side.

Figure 2. A 70-year-old female with severe bilateral festoons (A) before treatment; (B) showing a decrease in festoon volume after 3 bilateral injections of tetracycline at 9 months; and (C) postsurgery, month 10 of treatment, showing improvement of festoons.
Figure 3. A 65-year-old male with cascading festoons (A) before treatment; (B) showing a decrease in festoon volume after 4 bilateral injections of tetracycline at 9 months; and (C) postsurgery, month 12 of treatment, showing festoon improvement.

Figure 4. A 63-year-old female with cascading festoons (A) before treatment; (B) showing a decrease in festoon volume after 3 bilateral injections of tetracycline at 9 months; and (C) postsurgery, month 12 of treatment, showing festoon improvement.
The patients included in this study presented grade 3 bilateral festoons, according to the classification proposed by Lam et al. Three months after the injections of tetracycline 2%, the change in appearance of the festoons was visible due to dense adhesions and fibrosis at the local tissues. Repeated injections were performed for patients with partial response to the initial injections. In our experience, tetracycline injections are an effective treatment of festoons, although sequential injections are needed to produce desired volume change in very severe festoons. It is difficult to distribute a small fraction of tetracycline solution in different planes of the festoons. Tetracycline must be injected into the cavity of the festoon between the deep fascial plane and the orbicularis in the subcutaneous and intramuscular planes. The most common adverse effect with tetracycline injections is discomfort during the injection, usually lasting approximately 15-20 minutes. Periorbital nerve block (infraorbital and zygomaticofacial nerves) can relieve patient comfort during the injections.

These preliminary clinical observations encouraged us to submit 12 patients to subsequent treatment with the pinch technique to remove excess skin and canthopexy for final lateral support of the lower eyelid. The association of the procedures may represent an additional treatment modality for improving the appearance of severe lower eyelid festoons. While some residual festoon presence may remain after the combined procedure, the dramatic aesthetic change in the appearance of all patients is visible and satisfactory.

The limitations of this study include its retrospective nature and the reduced number of cases studied. Further studies may determine optimal treatment doses and intervals as well as any possible significant complications.

CONCLUSIONS

These preliminary results suggest that intraleisional injections of tetracycline 2% may offer a safe option to treat acquired, lower eyelid festoons. In our experience, tetracycline injections improve festoon appearance, and the procedure is well accepted by patients. This noninvasive procedure represents adjunct benefits to complementary surgical therapy. The association of these procedures may represent an additional treatment modality to improve the appearance of severe lower eyelid festoons.

Disclosures

The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding

The authors have no disclosures and no financial support was received for this study.

REFERENCES

1. Furnas DW. Festoons of orbicularis muscle as a cause of baggy eyelids. Plast Reconstr Surg. 1978;61(4):540-546.
2. Kpodzo DS, Nahai F, McCord CD. Malar mounds and festoons: review of current management. Aesthet Surg J. 2014;34(2):235-248.
3. Kikkawa DO, Lemke BN, Dortzbach RK. Relations of the superficial musculoaponeurotic system to the orbit and characterization of the orbitomalar ligament. Ophthalmic Plast Reconstr Surg. 1996;12(2):77-88.
4. Muzaffar AR, Mendelson BC, Adams WP Jr. Surgical anatomy of the ligamentous attachments of the lower lid and lateral canthus. Plast Reconstr Surg. 2002;110(3):873-884; discussion 897.
5. Pessa JE, Garza JR. The malar septum: the anatomic basis of malar mounds and malar edema. Aesthet Surg J. 1997;17(1):11-17.
6. Liapakis IE, Pashalis EI. Liposuction and suspension of the orbicularis oculi for the correction of persistent malar bags: description of technique and report of a case. Aesthet Plast Surg. 2012;36(3):546-549.
7. Jeon H, Geronemus RG. Successful noninvasive treatment of festoons. Plast Reconstr Surg. 2018;141(6):977e-978e.
8. Rosenberg GL. Correction of saddlebag deformity of the lower eyelids by superficial suction lipectomy. Plast Reconstr Surg. 1995;96(5):1061-1065.
9. Endara M, Oh C, Davison SP, Baker SB. The management of festoons. Clin Plast Surg. 2015;42(1):87-94.
10. Assadi M. Etiology and treatment of congenital festoons. Aesthet Plast Surg. 2018;42(4):1024-1032.
11. Hoening JF, Knutti D, de la Fuente A. Vertical subperiosteal midface-lift for treatment of malar festoons. Aesthet Plast Surg. 2011;35(4):522-529.
12. Newberry CI, Mc Crary H, Thomas JR, Cerrati EW. Updated management of malar edema, mounds and festoons: a systematic review. Aesthet Surg J. 2019;40(3):303-306.
13. Einan-Lifshitz A, Hartstein ME. Treatment of festoons by direct excision. Orbit. 2012;31(5):303-306.
14. Costin BR. Kinesio tape for treatment of lower eyelid festoons. Ophthalmic Plast Reconstr Surg. 2018;34(6):602.
15. Iverson SM, Patel RM. Dermal filler-associated malar edema: treatment of a persistent adverse effect. Orbit. 2017;36(6):473-475.
16. Scheiner AJ, Baker SS, Massry GG, et al. Laser management of festoons. In: Massry GG, Murphy MR, Azizzadeh B, eds. Master Techniques in Blepharoplasty and Periorbital Rejuvenation. New York, NY: Springer; 2011:211-221.
17. Hilton S, Schrumpf H, Buhren BA, Böke E, Gerber PA. Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients. Eur J Med Res. 2014;19:30.
18. Perry JD, Mehta VJ, Costin BR. Intraleisional tetracycline injection for treatment of lower eyelid festoons: a preliminary report. Ophthalmic Plast Reconstr Surg. 2015;31(1):50-52.
19. Godfrey KJ, Kally P, Dunbar KE, et al. Doxycycline injection for sclerotherapy of lower eyelid festoons and malar edema: preliminary results. Ophthalmic Plast Reconstr Surg. 2019;35(5):474-477.
20. Chon BH, Hwang CJ, Perry JD. Long-term patient experience with tetracycline injections for festoons. *Plast Reconstr Surg.* 2020;146(6):737e-743e.
21. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. *Pharmacol Res.* 2011;63(2):102-107.
22. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. *Adv Dent Res.* 1998;12(2):12-26.
23. Hurewitz AN, Lidonicci K, Wu CL, Reim D, Zucker S. Histologic changes of doxycycline pleurodesis in rabbits. Effect of concentration and pH. *Chest.* 1994;106(4):1241-1245.
24. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. *Ann Thorac Surg.* 1993;55(5):1115-1121; discussion 1121.
25. Antony VB, Rothfuss KJ, Godbey SW, Sparks JA, Hott JW. Mechanism of tetracycline-hydrochloride-induced pleurodesis. Tetracycline-hydrochloride-stimulated mesothelial cells produce a growth-factor-like activity for fibroblasts. *Am Rev Respir Dis.* 1992;146(4):1009-1013.
26. Gravelyn TR, Michelson MK, Gross BH, Sitrin RG. Tetracycline pleurodesis for malignant pleural effusions. A 10-year retrospective study. *Cancer.* 1987;59(11):1973-1977.
27. Moesen I, Mombaerts I. Subconjunctival injection of tetracycline 2% for chronic bulbar chemosis after transcutaneous four-eyelid blepharoplasty. *Ophthalmic Plast Reconstr Surg.* 2008;24(3):219-220.
28. Lam SM, Glasgold MJ, Glasgold RA, eds. *Complementary Fat Graphing.* Philadelphia, PA: Lippincott Williams & Wilkins; 2007:70.